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DEFINITION 
Crohn’s disease (CD) is an 
idiopathic inflammatory 
disorder of unknown etiology 
with genetic, immunologic, and 
environmental influences 
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
INTRODUCTION 
• The prevalence of CD appears to be higher in urban areas than 
in rural areas, and also higher in higher socio-economic classes 
• CD can affect any part of the gastrointestinal (GI) tract from 
the mouth to the anus. 
• In the 75% of patients with small intestinal disease, the 
terminal ileum is involved in 90%. 
• CD is a transmural process 
• The peak age of incidence of CD is in the third decade of life, 
with a decreasing incidence rate with age 
• Although more females than males have CD, the incidence 
rates among young children have been higher in males than in 
females during the past decade, and over time we may see an 
equalization of the sex distribution  
 
World Gastroenterology Organization, 2015  
 PATHOLOGY AND PATHOGENESIS 
• Although the etiology is complex, the most widely accepted 
hypothesis purports CD as an immune-mediated condition in 
genetically susceptible individuals, where disease onset is 
triggered by environmental factors that perturb the mucosal 
barrier, alter the healthy balance of the gut microbiota, and 
abnormally stimulate gut immune responses 
• Active CD is characterized by focal inflammation and 
formation of fistula tracts, which resolve by fibrosis and 
stricturing of the bowel 
• The bowel wall thickens and becomes narrowed and fibrotic, 
leading to chronic, recurrent bowel obstructions 
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447044/ 
GENETICS 
• The successful genome-wide association studies (GWASs) have 
provided a rational framework for new mechanistic insights 
and directions for research in CD 
• These most strongly and consistently implicate themes 
involving defective intracellular bacteria killing and innate 
immunity (CARD15/NOD2, IRGM, IL23R, LRRK2, and ATG16L1) 
and de-regulated adaptive immune responses, namely the 
interleukin-23 (IL-23) and T helper 17 (Th17) cell pathway 
(IL23R, IL12B (encoding IL-12p40), STAT3, JAK2, and TYK2) 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447044/ 
 PATHOGENESIS 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447044/ 
Crohn's disease (CD): 
multi-layer interactions 
in pathogenesis and 
clinical translation 
 Individual patients 
with CD have a unique 
pathogenic signature 
comprised of different 
contributions from 
each of these factors 
(stratification of patients on 
the basis of these signatures 
may lead to more focused, 
personalized, and successful 
therapies) 
CD: MACROSCOPIC FEATURES 
• CD is segmental with skip areas in the 
midst of diseased intestine 
• Endoscopically, aphthous or small 
superficial ulcerations characterize mild 
disease; in more active disease, stellate 
ulcerations fuse longitudinally and 
transversely to demarcate islands of 
mucosa that frequently are 
histologically normal 
• This “cobblestone” appearance is 
characteristic of CD, both edoscopically 
and by barium radiography 
• Active CD is characterized by focal 
inflammation and formation of fistula 
tracts, which resolve by fibrosis and 
stricturing of the bowel 
• The bowel wall thickens and becomes 
narrowed and fibrotic, leading to 
chronic, recurrent bowel obstructions 
 
CD of the colon showing thickening of the wall, 
with stenosis, linear serpiginous ulcers and 
cobblestoning of the mucosa. 
Harrison's Principles of Internal Medicine, 20e 
CD: MICROSCOPIC FEATURES 
Medium-power view of Crohn’s colitis showing mixed acute and chronic inflammation, crypt 
atrophy, and multiple small epithelioid granulomas in the mucosa 
Harrison's Principles of Internal Medicine, 20e 
CLINICAL FEATURES  
Hallmark/cardinal symptoms of Crohn’s disease include 
abdominal pain, diarrhea, and fatigue; weight loss, fever, 
growth failure, anemia, recurrent fistulas, or extraintestinal 
manifestations can also be presenting features 
The most common symptom of Crohn’s disease is chronic 
diarrhea  
Abdominal pain, often localized to the right lower quadrant 
of the abdomen and worsened postprandially, is common.  
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
CLINICAL FEATURES  
The site of disease also influences the clinical manifestations! 
• Ileocolitis - a chronic history of recurrent episodes of right lower 
quadrant pain and diarrhea. Sometimes the initial presentation 
mimics acute appendicitis with pronounced right lower quadrant 
pain, a palpable mass, fever, and leukocytosis 
• Pain is usually colicky; it precedes and is relieved by defecation 
• A low-grade fever is usually noted 
• High-spiking fever suggests intraabdominal abscess formation 
• Weight loss is common—typically 10–20% of body weight—and 
develops as a consequence of diarrhea, anorexia, and fear of eating 
• Over several years, persistent inflammation gradually progresses to 
fibrostenotic narrowing and stricture; diarrhea will decrease and be 
replaced by chronic bowel obstruction 
Harrison's Principles of Internal Medicine, 20e 
CLINICAL FEATURES  
The site of disease also influences the clinical manifestations! 
• Jejunoileitis - extensive inflammatory disease is associated with a 
loss of digestive and absorptive surface, resulting in malabsorption 
and steatorrhea 
• Intestinal malabsorption can cause anemia,  hypoalbuminemia, 
hypocalcemia, hypomagnesemia, coagulopathy, and hyperoxaluria 
with nephrolithiasis in patients with an intact colon 
• Diarrhea is characteristic of active disease; its causes include (1) 
bacterial overgrowth in obstructive stasis or fistulization, (2) bile 
acid malabsorption due to a diseased or resected terminal ileum, 
and (3) intestinal inflammation with decreased water absorption 
and increased secretion of electrolytes 
Harrison's Principles of Internal Medicine, 20e 
CLINICAL FEATURES  
The site of disease also influences the clinical manifestations! 
• Colitis and perianal disease - present with lowgrade fevers, malaise, 
diarrhea, crampy abdominal pain, and sometimes hematochezia 
• Gross bleeding is not as common as in Ulceritive Colitis and appears in 
about one-half of patients with exclusively colonic disease 
• Pain is caused by passage of fecal material through narrowed and 
inflamed segments of the large bowel 
• Colonic disease may fistulize into the stomach or duodenum, causing 
feculent vomiting, or to the proximal or mid-small bowel, causing 
malabsorption by “short circuiting” and bacterial overgrowth 
• Perianal disease affects about one-third of patients with Crohn’s colitis 
and is manifested by incontinence, large hemorrhoidal tags, anal 
strictures, anorectal fistulae, and perirectal abscesses 
Harrison's Principles of Internal Medicine, 20e 
CLINICAL FEATURES  
The site of disease also influences the clinical 
manifestations! 
• Gastroduodenal disease -  symptoms and signs of upper GI 
tract disease include nausea, vomiting, and epigastric pain 
• Patients usually have an Helicobacter pylori–negative 
gastritis 
• The second portion of the duodenum is more commonly 
involved than the bulb 
• Fistulas involving the stomach or duodenum arise from the 
small or large bowel and do not necessarily signify the 
presence of upper GI tract involvement. 
• Patients with advanced gastroduodenal CD may develop a 
chronic gastric outlet obstruction 
Harrison's Principles of Internal Medicine, 20e 
CLINICAL FEATURES  
Extraintestinal 
manifestations 
arthropathy  
(both axial and peripheral);  
dermatological (including 
pyoderma gangrenosum and 
erythema nodosum (Figure 1));  
ocular  
(including uveitis (Figure 2), 
scleritis, and episcleritis);  
hepatobiliary disease 
(i.e., primary sclerosing 
cholangitis). 
Other extraintestinal 
complications  
thromboembolic (both 
venous and arterial);  
metabolic bone 
diseases;  
osteonecrosis;  
cholelithiasis;  
nephrolithiasis.  
 
 
 
 
 
 
 
 
 
A number of other 
immune-mediated 
diseases are 
associated with 
Crohn’s disease, 
including asthma, 
chronic bronchitis, 
pericarditis, 
psoriasis, celiac 
disease, 
rheumatoid 
arthritis, and 
multiple 
sclerosisions 
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
CLINICAL FEATURES : Extraintestinal 
manifestations 
Figure 1. 
Erythema 
nodosum on 
legs. 
https://www.verywellhealth.com/erythema-nodosum-1943012 
CLINICAL FEATURES: 
Extraintestinal manifestations 
Figure 2. 
Uveitis: a form 
of eye 
inflammation. 
It affects the 
middle layer of 
tissue in the 
eye wall (uvea) 
https://www.stepwards.com/?page_id=2371 
CLINICAL FEATURES: 
Extraintestinal manifestations 
Figure 3. 
Episcleritis and 
scleritis are 
characterized 
by red, 
inflamed-
looking whites 
of the eye, 
mild pain, and 
watery eyes 
https://www.stepwards.com/?page_id=2371 
DIAGNOSIS  
Routine laboratory investigation 
• Initial laboratory investigation should include evaluation for 
inflammation, anemia, dehydration, and malnutrition.  
Stool examination   
 
• Routine fecal examinations and cultures should be carried out to eliminate 
bacterial, viral, or parasitic causes of diarrhea.  
• Testing for Clostridium difficile (should be considered even in the absence of 
antecedent antibiotics) — should be carried out within 2 hours of passage of 
stools.  
• A check for occult blood or fecal leukocytes  
• Lactoferrin, α1-antitrypsin. The main reason for listing this test is to rule out 
intestinal inflammation, rather than using it as a positive diagnostic test. It may not 
be available in developing countries, but it can be undertaken relatively 
inexpensively and easily with rapid-turnaround slide-based enzyme-linked 
immunoassay (ELISA) tests.  
• Calprotectin — a simple, reliable, and readily available test for measuring IBD 
activity — may be better for UC than CD; the rapid fecal calprotectin tests could be 
very helpful in developing countries.  
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
DIAGNOSIS   
Routine laboratory investigation 
Blood examination  
 
• Complete blood count (CBC)  
• Erythrocyte sedimentation rate, C-reactive protein levels correlate imperfectly with 
inflammation and disease activity  
• Electrolytes and albumin, ferritin, calcium, magnesium, vitamin B12.  
• Serum ferritin may be elevated in active IBD, and may be in the normal range even in 
the face of severe iron deficiency 
• Liver enzyme and function testing — international normalized ratio (INR), bilirubin, 
albumin.  
• Human immunodeficiency virus (HIV) — additional opportunistic infection work-up, 
hepatitis B virus (HBV), hepatitis C virus (HCV), varicella zoster virus (VZV), 
immunoglobulin G (IgG)  
• Perinuclear antineutrophil cytoplasmic antibody (p-ANCA) and anti-Saccharomyces 
cerevisiae antibodies (ASCA) for cases of unclassified IBD.  
• — Positive p-ANCA and negative ASCA tests suggest UC.  
• — Negative p-ANCA and positive ASCA tests suggest CD.  
• Celiac antibody testing should be pursued unless presentations include obviously 
nonceliac features such as fistulas, perineal disease, and blood in the stool 
World Gastroenterology Organization, 2015 ; 
DIAGNOSIS  
Endoscopy 
Colonoscopy with intubation of the terminal ileum and biopsy is 
recommended as part of the initial evaluation of patients with suspected 
IBD. 
Mucosal changes suggestive of CD include mucosal nodularity, edema, 
ulcerations, friability, and stenosis 
• Upper endoscopy should only be performed in patients with upper gastrointestinal 
signs and symptoms.  
• Video capsule endoscopy (VCE) is a useful adjunct in the diagnosis of patients with 
small bowel Crohn’s disease in patients in whom there is a high index 
 
Endoscopic scoring systems: the Crohn’s Disease Endoscopic Index of Severity (CDEIS) 
and the Simple Endoscopic Score for Crohn’s disease (SES-CD) of suspicion of disease.  
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
DIAGNOSIS  
High-definition white-
light endoscopy of 
severe Crohn’s disease 
with multiple 
longitudinal ulcers and 
spontaneous bleeding 
of the inflamed 
mucosa. 
https://www.hindawi.com/journals/grp/2012/301541/fig1/ 
DIAGNOSIS  
Imaging studies 
Computed tomography enterography (CTE) is sensitive for the 
detection of small bowel disease in patients with Crohn’s disease 
and is comparable to magnetic resonance enterography (MRE). 
Because of the absence of any radiation exposure, MRE should 
be used preferentially in young patients (<35 y.o.) and in patients 
in whom it is likely that serial exams will need to be performed 
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
Classification of Disease Severity 
in Crohn’s Disease 
There is no “gold standard” for determining disease activity.  
Disease activity depends on heterogeneous clinical measures, impact on quality of life, 
complications of disease, and complications of therapy. 
These assessments are important in that they allow the clinician to make decisions about 
disease management. 
https://www.ncbi.nlm.nih.gov/books/NBK424370/table/T5/ 
CRP is usually increased 
The Crohn's Disease Activity 
Index (CDAI) 
The Crohn's Disease Activity Index 
(CDAI) allows quantitation and tracking 
of disease activity in adults with 
Crohn’s disease. 
The CDAI may have wide variation in 
definitions and scoring in real world 
use. 
Lab variations of “normal” hematocrit 
in men and women can often lead to 
markedly different CDAI scores; 
similarly, changes in weight can lead to 
score differences as well. 
CDAI of 150-450 is used as a marker of 
active Crohn's disease. The higher the 
score, the more severe the disease 
activity. 
https://www.mdcalc.com/crohns-disease-activity-index-cdai#pearls-pitfalls 
DIAGNOSIS   
Monitoring disease activity 
• Fecal calprotectin and fecal lactoferrin measurements may have an 
adjunctive role in monitoring disease activity. 
• Serum CRP is relatively nonspecific for the inflammation of Crohn’s 
disease, but in select patients serial measurements may have a role 
in monitoring disease activity and response to therapy.  
• Periodic cross-sectional imaging (CTE, MRE) may be considered in 
monitoring response to therapy in certain patients with small bowel 
Crohn’s disease.  
• Mucosal healing as determined by endoscopy is a goal of therapy.  
• a. Endoscopic scores have been developed that are reliable in 
measuring degree of mucosal healing and may be used to monitor 
response to therapy.  
• b. Evaluation of the ileum for post-operative endoscopic recurrence 
by colonoscopy within a year after ileocolonic resection may help 
guide further therapy.  
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
DIFFERENTIATING BETWEEN  
UC AND CD 
World Gastroenterology Organization, 2015 ; 
Management of CD 
• The goal of treatment is to:  
•  Improve and maintain patients’ general well-being (optimizing 
the quality of life, as seen from the patient’s perspective)  
•  Treat acute disease:  
• — Eliminate symptoms and minimize side effects and long-
term adverse effects  
• — Reduce intestinal inflammation and if possible heal the 
mucosa  
•  Maintain corticosteroid-free remissions (decreasing the 
frequency and severity of recurrences and reliance on 
corticosteroids)  
•  Prevent complications, hospitalization, and surgery  
•  Maintain good nutritional status  
World Gastroenterology Organization, 2015 ; 
Management of CD 
Diet and lifestyle considerations  
• The impact of diet on inflammatory activity in UC/CD is poorly 
understood, but dietary changes may help reduce symptoms:  
• During increased disease activity, it is appropriate to decrease 
the amount of fiber. Dairy products can be maintained unless 
not tolerated.  
• Smoking cessation benefits patients with CD in relation to 
their disease course  
• Reduction of stress and better stress management may 
improve symptoms or the patients’ approach to their disease  
 
 
World Gastroenterology Organization, 2015 ; 
MEDICAL THERAPY 
• Medical treatment of CD is usually divided into induction and 
maintenance therapy 
• These phases of treatment involve achieving control of 
inflammation relatively quickly (over 3 months or less) and then 
sustaining that control for prolonged periods of time (beyond 3 
months) 
• Treatment is generally chosen according to the patient’s risk profile 
and disease severity, with a goal of controlling inflammation and, 
consequently, symptoms arising from active inflammation 
• Medical therapy used to treat CD includes the categories of 5-
aminosalicylates (5-ASA), antibiotics, corticosteroids, 
immunomodulators, and biologics (the anti-TNF agents infliximab, 
adalimumab, certolizumab pegol; agents targeting leukocyte 
trafficking, including vedolizumab, natalizumab; and the anti-p40 
(anti-IL-12/23) antibody, ustekinumab). 
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
MEDICAL THERAPY 
 5-aminosalicylates 
• Sulfasalazine (in the doses of 3–6 g daily) is an effective therapy for 
treatment of symptoms of patients with mild to moderately active colonic 
CD and/or ileocolonic CD, but not in those with isolated small bowel disease 
Corticosteroids 
• Corticosteroids (such as prednisone and methylprednisolone) are used 
primarily for the treatment of flares of CD.  
• Oral formulations may be used for mild to moderate disease, whereas 
systemic corticosteroids are used for moderate to severe disease. They have 
historically been used as a “bridge” to permit symptom control until 
immunomodulators and/or biologic agents become effective and enable 
mucosal healing. 
• Systemic corticosteroids are ineffective for maintenance therapy in patients 
with CD. 
• The appropriate prednisone equivalent doses used to treat patients with active CD are at doses 
ranging from 40 to 60 mg/day  
• Higher doses, such as 1 mg/kg body weight per day of prednisolone, have also been studied. These 
doses are typically maintained for 1–2 weeks and tapered at 5 mg weekly until 20 mg and then 2.5–
5.0 mg weekly. 
• Corticosteroid tapers should generally not exceed 3 months. 
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
MEDICAL THERAPY 
Antimicrobial therapy  
• Although widely used in the past, the primary role of 
antibiotics for the treatment of luminal CD is not established.  
• Metronidazole is not more effective than placebo at inducing 
remission in patients with CD.  
• Broad-spectrum antibiotics are used for the treatment of 
pyogenic complications (e.g., intra-abdominal and mesenteric 
abscesses) in patients with CD. 
• Metronidazole may be helpful to prevent postoperative 
recurrence in CD. 
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
MEDICAL THERAPY 
Immunomodulators 
• In patients with moderate-to-severe CD who remain symptomatic 
despite current or prior corticosteroid therapy, the thiopurine analogs 
(6-mercaptopurine and azathioprine) may be used 
• Methotrexate, when given subcutaneously (SC) or intramuscularly (IM), 
is also effective as a steroid-sparing agent 
• Thiopurine agents and methotrexate are not effective agents for short-
term induction in active, symptomatic disease because of their relatively 
slow onset of action, between 8 and 12 weeks. 
• The use of methotrexate in combination with steroids is effective for 
treatment of moderately active steroid-dependent/resistant CD 
• Azathioprine (at maximal doses of 1.5–2.5 mg/kg/day), 6-
mercaptopurine (at maximal doses of 0.75– 1.5 mg/kg day), or 
methotrexate (15–25 mg SC/IM once weekly) may be used in treatment 
of active CD 
• Azathioprine and 6-mercaptourine are effective therapies and should be 
considered for treatment of patients with Crohn’s disease for 
maintenance of remission 
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
Medical Therapy 
Anti-TNF agents 
• The anti-TNF antibodies (infliximab, adalimumab, and 
certolizumab pegol) are effective for treatment of patients 
with CD who respond inadequately to treatment with 
corticosteroids, thiopurines, and methotrexate 
• Before initiation of anti-TNF therapy, assessment for latent and 
active tuberculosis and other latent opportunistic infections such 
as histoplasmosis and blastomycosis when potentially present 
should be initiated 
• Assessment for the presence of viral hepatitis should be 
performed in all CD patients before the initiation of anti-TNF 
therapy. 
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
MEDICAL THERAPY 
• NOVEL AGENTS 
• Some of the other agents under different stages of 
development for the treatment of patients with CD include 
other anti-integrins such as etrolizumab (which is a dual action 
anti-integrin that inhibits both α 4β 7 and α Eβ 7) or ozanimod 
(a potent sphingosine1-phosphate receptor modulator that 
inhibits the egress of lymphocytes from lymph nodes)  
• Several other agents in early phases of development include 
the anti-IL-23 agents, risankizumab and brazikumab, and the 
selective Janus kinase-1 inhibitors, filgotinib and upadacitinib 
(formerly ABT-494) 
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
MEDICAL THERAPY 
Agents targeting leukocyte trafficking 
• Inhibitors of leukocyte trafficking (Natalizumab, an anti-α 4 
integrin antibody etc) recently have expanded the therapeutic 
options for patients with CD 
Agents targeting IL-12/23 (anti-p40 antibody) 
• Ustekinumab should be given for moderate-to-severe Crohn’s 
disease patients who have failed previous treatment with 
corticosteroids, thiopurines, methotrexate, or anti-TNF 
inhibitors, or who have had no prior exposure to anti-TNF 
inhibitors 
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
MEDICAL THERAPY 
MAINTENANCE THERAPY OF LUMINAL CROHN’S DISEASE 
• Once remission is induced with corticosteroids, a thiopurine or 
methotrexate should be considered 
• Corticosteroids are not indicated for long-term treatment of CD because of 
lack of efficacy for maintenance of remission and adverse effects 
• There are several studies that have demonstrated that azathioprine 2.5 
mg/kg/day and 6 mercaptopurine 1.5 mg/kg/day are effective for the 
maintenance of remission in CD 
• Oral 5-aminosalicylic acid has not been demonstrated to be effective for 
maintenance of medically induced remission in patients with Crohn’s 
disease, and is not recommended for long-term treatment 
• Anti-TNF therapy, specifically infliximab (5 or 10 mg/kg every 8 weeks), 
adalimumab, and certolizumab pegol, should be used to maintain 
remission of anti-TNF-induced remission 
ACG Clinical Guideline: Management of Crohn’s disease in Adults doi: 10.1038/ajg.2018.27; 
Case Report 1.4. 
• A 65-year male chronic smoker was admitted to 
the medicine ward in hospital as a case of acute 
exacerbation of chronic obstructive pulmonary 
disease with history of diarrhea and abdominal 
pain for the last 14 days. 
• However patient developed features of acute 
intestinal obstruction in the form of severe 
abdominal pain, gross abdominal distention, 
absolute constipation while on medical treatment 
for 4-5 days.  
• In view of patients acute abdominal condition 
exploratory laparotomy was performed.  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336915/ 
Case Report 2.4. 
• Intraoperatively the entire small bowel was grossly dilated 
with dense interloop adhesions in the terminal ileum with 
multiple gangrenous patches.  
•  About 500-600 ml pus present in between the adhered loops 
of bowel was suggestive of an old terminal ileal perforation 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336915/ 
Intraoperative picture 
showing multiple 
gangrenous patches in 
terminal ileum 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336915/ 
Case Report 4.4. 
• The gangrenous bowel was resected out and an ileostomy with a distal 
mucus fistula was made. 
• Histopathological examination showed narrowed areas of ileum with 
thickening and congestion of all the layers along with focal non 
caseating granulomas in the serosal layer.  
• Chronic inflammatory infiltrates were present in all the layers with 
acute inflammatory cells in the serosal layer. Thus, a diagnosis of 
Crohn's disease leading to chronic intestinal obstruction with 
superadded bacterial infection of serosal layer was made. 
• Postoperatively, the patient was put on broad spectrum antibiotics and 
chest care was taken.  
• The patient was doing well for a period of more than one month after 
surgery but unfortunately he had collapse of right lung with pleural 
effusion and died of respiratory cause. 
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336915/ 
Case Report 1.12. 
•  The patient was a 27 years old female with a chief complaint 
of diarrhea for 3 months, and fever and night sweating for 
more than 2 months 
 
•  Three months ago, the patient began having yellow watery 
diarrhea at a frequency of 3-4 times a day, and mushy stool 
that occasionally contained mucus, accompanied with 
periumbilical and the right abdominal dull pain  
 
•  The symptoms failed to respond to medical treatment  
 
 Int J Clin Exp Med 2016;9(10):20362-20366 www.ijcem.com /ISSN:1940-5901/IJCEM0025649 
Case Report 2.12. 
•  During about two months, she developed low-grade fever 
(37.4-38.0°C), usually in the afternoon, night sweating, 
fatigue, anorexia and weight loss  
•  Colonoscopy showed no significant abnormality in the colon 
mucosa 
• Chest X-ray was not remarkable 
• Purified protein derivative tuberculin (PPD) test was strongly 
positive, and a diagnosis of intestinal tuberculosis was made 
• On April 11, 2012, the patient began receiving anti-TB 
treatment with isoniazid, rifampicin and ethambutol in 
another hospital  
• Two weeks later, ethambutol was withdrawn   
 
 Int J Clin Exp Med 2016;9(10):20362-20366 www.ijcem.com /ISSN:1940-5901/IJCEM0025649 
Case Report 3.12. 
• However, the symptoms were not significantly relieved 
• She had a persistent fever (the highest temperature 39.5°C) and 
productive cough 
• She was sent to our clinic for further diagnosis and treatment, 
where laboratory tests showed that the autoantibody spectrum, 
anti-O and rheumatoid factor were within the normal range 
• TB antibody test in another hospital a month ago was weakly 
positive 
• The abdominal contrast-enhanced CT showed no abnormal signs, 
and the diagnosis of TB infection was questioned 
• Oral anti-TB treatment with isoniazid and rifampicin was continued, 
but high fever remained unrelieved, accompanied with multiple oral 
ulcers 
• Gastroscopy and lung CT scan in another hospital were not 
remarkable, and the diagnosis of Behcet’s disease (type of vasculitis) 
was suspected  
• No other special drug was administered 
 
 Int J Clin Exp Med 2016;9(10):20362-20366 www.ijcem.com /ISSN:1940-5901/IJCEM0025649 
Case Report 4.12. 
• A diagnosis of Behcet’s disease was made in the outpatient department of 
rheumatology of our hospital, and oral prednisone (15 mg daily) was 
prescribed 
• However, the patient still had intermittent fever (39.0°C), and she visited our 
hospital again for further treatment 
• Since the onset of the disease, she had lost about 10 kg body weight 
• She had been previously healthy and prone to develop mouth ulcers that were 
difficult to heal 
• Admission examination: T 36.4°C, P 102 bpm, R 18/min, BP 107/73 mmHg; 
conscious; mild anemia appearance; obvious body weight loss; superficial 
lymph nodes impalpable; heart and lungs not remarkable; abdomen soft, right 
side abdomen tender without rebound pain; liver and spleen not palpable 
below costal margin; no percussion pain over liver and kidney areas; no edema 
in the lower extremities  
• Laboratory examinations: hemoglobin 109 g/L, platelet count 577 × 109/L, 
urine leukocytes 1+, stool occult blood positive; stool culture: not abnormal; 
blood biochemistry: globulin 37.00 g/L, total cholesterol 5.76 mmol/L; 
coagulation: activated partial thromboplastin time 50.70 sec, fibrinogen 7.30 
g/L, ultra-sensitive C-reactive protein 84.4 mg/L, ESR 86-95 mm/h 
 
 Int J Clin Exp Med 2016;9(10):20362-20366 www.ijcem.com /ISSN:1940-5901/IJCEM0025649 
Case Report 5.12. 
• TB antibody negative; PPD strongly positive; immune function monitoring: 
serum complement C31.87 g/L; rheumatology detection: ANA, ENA, ANCA 
normal  
• Protein electrophoresis: γ globulins within normal range, immunoglobulin 
normal; infection related detection: to luidine Red agglutination test: HIV, 
cytomegalovirus, EB virus, TORCH four, Weil-Felix reaction, Widal reactions 
are normal 
• Procalcitonin 0.06 ng/ml, ferritin 183.3 ng/ml 
• Eye examination: normal 
• Examinations in other hospitals: thyroid function, tumor markers, protein 
electrophoresis γ globulin, coagulation, Legionella antibodies, 
Mycoplasma pneumoniae antibodies, ANA, ANCA, parasite eggs 
(roundworm, hookworm, whipworm, pinworm) not remarkable; 
chlamydia antibody (+) 
• Liver function: globulin, abdominal ultrasonography: cholestasis, sediment 
ocean stones, uterine adnexa normal; thyroid ultrasound: no exception, 
colonoscopy, lungs, pelvic, intestinal CT normal; cerebrospinal fluid 
normal; bone marrow puncture: normal 
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Case Report 6.12. 
• Capsule endoscopy after admission showed multiple ulcers of the 
jejunum and ileum! 
• Enteroscopy showed congestion, edema and easy bleeding of the 
terminal ileum, and multiple shallow ulcers measuring 0.3 * 0.4-0.8 
* 1.0 cm, from which biopsy specimens were obtained 
• Multiple irregular ulcers of different sizes and shapes were seen 
from the anus 20 cm to the ileocecal valve; nodular change was 
seen in part of the ulcer edges; the lesions were in a jumping 
distribution; and the mucosa between the ulcers was normal 
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Case Report 7.12. 
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Case Report 8.12. 
• Shallow ulcers were seen in the local anal canal mucosa 
• Positron emission tomography-computed tomography (PET-
CT) showed the following:  
1) multiple small patches were seen in the colon and small 
intestine, where the punctate metabolism was increased; no 
obvious thickening and swelling were seen in the intestinal wall, 
based on which inflammatory infection or tuberculosis was 
suspected; 
2) no significant high metabolic tumor lesion was seen in other 
organs of the 
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Case Report 9.12. 
• Pathology study suspected the diagnosis of severe chronic 
inflammation in the terminal ileum, ascending colon and 
sigmoid colon mucosa; acute active (moderate) reactive 
lymphoid follicular hyperplasia and inflammatory necrosis 
• Further examinations were suggested to exclude Behcet’s 
disease, Crohn’s disease and intestinal tuberculosis 
• Immunohistochemistry excluded lymphoma and parasitic 
infection 
• Ultrasonic colonoscopy showed that the colonic mucosa was 
clear, intestinal wall with slightly thickened, submucosa 
showed High echo, muscularis propria was involved, the 
ultrasound presentation is consistent with the diagnosis of 
Crohn’s disease, and did not supported lymphoma 
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Case Report 10.12. 
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Case Report 11.12. 
• Treatment with methylprednisolone (60 mg * 5 d) and 
quinolone antibiotics were initiated on June 20, 2012, 
followed by oral prednisone (50 mg) for a month  
• After the hormone therapy, temperature of the patient 
returned to normal, diarrhea disappeared, and appetite was 
improved, with occasional abdominal discomfort  
• Ultra-sensitive C-reactive protein re-examination showed 36-
26 mg/L and ESR 64 mm/h 
• Gradually hormone was replaced by immunosuppressive 
agents after one month. 
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DISTINGUISHING BETWEEN 
TUBERCULOSIS AND CROHN’S DISEASE  
World Gastroenterology Organization, 2015 ; 
Case Report 12.12. 
Discussion 
• Intestinal tuberculosis and Crohn’s disease are among important intestinal inflammatory 
diseases, the incidence of which is on the rise in recent years  
• The diagnosis of Crohn’s disease mainly depends on the following evidence: 1) discontinuous 
or segmental lesions; 2) cobblestoning and longitudinal ulcers; 3) inflammatory lesions of the 
entire intestinal wall; 4) non-caseous granuloma; 5) the presence of fistula; and 6) anal lesions 
(excluding intestinal tuberculosis, amoebic dysentery, Yersinia infection, chronic intestinal 
infection, eliminate intestinal lymphoma, diverticulitis, ischemic colitis and Behcet’s disease). 
1, 2, 3 are suspected, plus 4, 5, 6 any one can be diagnosed. 4 plus 1, 2, 3 any two can be 
diagnosed  
• The diagnosis of tuberculosis mainly depends on the presence of the caseous necrotizing 
granulomatous bowel wall or mesenteric lymph nodes, histological biopsy, positive culture  
• Intestinal tuberculosis: support: PPD strong positive, fever, suppressed menstruation and 
tuberculosis symptoms. nonsupport: anti-TB therapy is invalid, intestinal change is not typical  
• In the short term, it is necessary to review colonoscopy, endoscopic ultrasound is an 
important means to identify the Crohn’s disease 
• When the treatment is invalid of the patient, the diagnosis and the relevant checks need to 
reconsider.  
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